文献速递糖尿病

非奈利酮在慢性肾脏病合并2型糖尿病患者中按基线HbA1c和胰岛素使用情况的分析:FIDELIO-DKD研究

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
PubMed 文献 · Diabetes Care · 2022-01-01

FIDELIO-DKD研究事后分析,按基线HbA1c(<7.5%或≥7.5%)和胰岛素使用情况分层,评估非奈利酮对肾脏和心血管复合终点的影响。结果显示非奈利酮降低肾脏和心血管结局风险不受基线HbA1c水平或胰岛素使用影响,不良事件相似。

要点

  • 非奈利酮降低肾脏复合终点风险不依赖基线HbA1c水平(交互P=0.41)和胰岛素使用(交互P=0.56)。
  • 非奈利酮降低心血管复合终点风险不依赖基线HbA1c水平(交互P=0.70)和胰岛素使用(交互P=0.33)。
  • 高HbA1c水平与心血管风险增加相关,但不影响肾脏事件风险。

核心结论

  • 非奈利酮降低慢性肾脏病合并2型糖尿病患者的肾脏和心血管结局风险,且风险降低似乎不受HbA1c水平或胰岛素使用影响。

研究设计与样本

  • FIDELIO-DKD试验的事后分析,纳入2型糖尿病、尿白蛋白/肌酐比值30-5,000 mg/g、估算肾小球滤过率25至<75 mL/min/1.73 m2且接受优化肾素-血管紧张素系统阻断治疗的患者,随机接受非奈利酮或安慰剂。
  • 共5,674例患者,其中3,637例(64.1%)基线接受胰岛素治疗;5,663例纳入HbA1c分析,2,794例(49.3%)基线HbA1c <7.5%(58 mmol/mol)。
  • 按基线胰岛素使用和基线HbA1c <7.5%(58 mmol/mol)或≥7.5%进行亚组分析。

主要发现

  • 非奈利酮显著降低肾脏复合终点风险,与基线HbA1c水平(交互P=0.41)和胰岛素使用(交互P=0.56)无关。
  • 非奈利酮降低心血管复合终点发生率,与基线HbA1c水平(交互P=0.70)和胰岛素使用(交互P=0.33)无关。
  • 基线HbA1c水平不影响肾脏事件风险,但心血管风险随HbA1c水平升高而增加。
  • 尿白蛋白/肌酐比值降低在各亚组中一致。
  • 不良事件在基线HbA1c水平和胰岛素使用各亚组间相似;因高钾血症停药的非奈利酮治疗患者很少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Finerenone significantly improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial. We explored whether baseline HbA1c level and insulin treatment influenced outcomes. RESEARCH DESIGN AND METHODS: Patients with T2D, urine albumin-to-creatinine ratio (UACR) of 30-5,000 mg/g, estimated glomerular filtration rate (eGFR) of 25 to <75 mL/min/1.73 m2, and treated with optimized renin-angiotensin system blockade were randomly assigned to receive finerenone or placebo. Efficacy outcomes included kidney (kidney failure, sustained decrease ≥40% in eGFR from baseline, or renal death) and cardiovascular (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) composite endpoints. Patients were analyzed by baseline insulin use and by baseline HbA1c <7.5% (58 mmol/mol) or ≥7.5%. RESULTS: Of 5,674 patients, 3,637 (64.1%) received insulin at baseline. Overall, 5,663 patients were included in the analysis for HbA1c; 2,794 (49.3%) had baseline HbA1c <7.5% (58 mmol/mol). Finerenone significantly reduced risk of the kidney composite outcome independent of baseline HbA1c level and insulin use (Pinteraction = 0.41 and 0.56, respectively). Cardiovascular composite outcome incidence was reduced with finerenone irrespective of baseline HbA1c level and insulin use (Pinteraction = 0.70 and 0.33, respectively). Although baseline HbA1c level did not affect kidney event risk, cardiovascular risk increased with higher HbA1c level. UACR reduction was consistent across subgroups. Adverse events were similar between groups regardless of baseline HbA1c level and insulin use; few finerenone-treated patients discontinued treatment because of hyperkalemia. CONCLUSIONS: Finerenone reduces kidney and cardiovascular outcome risk in patients with CKD and T2D, and risks appear consistent irrespective of HbA1c levels or insulin use.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Rossing P, Burgess E, Agarwal R, et al. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care. 2022. PMID: 35061867. doi:10.2337/dc21-1944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。